权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Technical feasibility for the Revive + Adrenaline Auto-injector

Revive 肾上腺素自动注射器的技术可行性

基本信息

批准号：
56306
负责人：
金额：
$ 24.3万
依托单位：
REVIVE INNOVATIONS + LIMITED
依托单位国家：
英国
项目类别：
Study
财政年份：
2020
资助国家：
英国
起止时间：
2020 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=56306
关键词：
Technical feasibility Revive Adrenaline Auto

项目摘要

An adrenaline auto-injector (AAI) is prescribed to people who are susceptible to severe allergies that put them at risk of anaphylaxis -- a life threatening allergic reaction. Despite medical advice to carry the injector on person at all times, our user studies show:1. People do not carry them nearly as much as they should2. Not receiving adrenaline for an anaphylactic reaction is the biggest common factor in fatalities as adrenaline is the only drug known to prevent death due to anaphylaxis.Revive is a new AAI concept developed as a graduation project at the Royal College of Art (RCA). This project seeks to extend the promising results of this prior phase wherein a proof of concept(PoC) was developed. Designed with the patient at its centre, it's much smaller size makes it easy to carry and its form makes it discreetly fit within a patient's life. These combine like never before to counteract the identified problems of being too large to practically carry continuously and adverse impacts on quality of life from an obvious medical form and associated stigma. Revive achieves this through a fresh examination of how a syringe should be designed for an AAI. The proprietary needle injection system concept has been awarded InnovationRCA's support and is patent pending in the UK.We have developed a PoC where we tested functionality and medicine dosage. Revive also has simplified instructions designed to improve accurate use. Revive, unlike most current offerings in the market, incorporates a variety of needle lengths.Now, the team seeks to extend this achievement by conducting a technical feasibility study through the engineering audit of the concept.

肾上腺素自动注射器(AAI)是为容易发生严重过敏的人开的，这会使他们面临过敏反应的风险--一种危及生命的过敏反应。尽管医学建议总是随身携带注射器，但我们的用户研究表明：1.人们携带的注射器数量几乎没有他们应该携带的那么多。因为肾上腺素是唯一已知的预防过敏死亡的药物，所以不接受肾上腺素过敏反应是导致死亡的最大常见因素。Revive是皇家艺术学院(RCA)作为毕业设计开发的一个新的人工智能概念。该项目力求扩大前一阶段的可喜成果，在该阶段开发了概念验证(PoC)。它的设计以病人为中心，尺寸小得多，便于携带，其形状使其谨慎地适合病人的生活。它们前所未有地结合在一起，抵消了已确定的问题，即太大而不能实际持续存在，以及明显的医疗形式和相关耻辱对生活质量的不利影响。REVIVE通过重新检查应该如何为人工智能设计注射器来实现这一点。专有的针头注射系统概念已经获得了InnovationRCA的支持，并正在英国申请专利。我们已经开发了一种PoC，我们在其中测试了功能和药物剂量。REVIVE还简化了使用说明，旨在提高精确度。与目前市场上的大多数产品不同，REVIVE包含多种长度的针头。现在，该团队试图通过对该概念进行工程审计来进行技术可行性研究，以扩展这一成就。